Search

Your search keyword '"Cherfils, Corinne"' showing total 15 results
Start Over Author "Cherfils, Corinne"
15 results on '"Cherfils, Corinne"'

2. Diagnosis of chylous abdominal effusions: what is the triglyceride threshold value?

Author

Lefrère, Bertrand, Curis, Emmanuel, Bittar, Randa, Levasseur, Antoine, Grès, Pierre, Guilbert, Zoé, Zenati, Belkacem, Cherfils, Corinne, Sakka, Mehdi, Bonnefont-Rousselot, Dominique, Lefrère, Bertrand, Curis, Emmanuel, Bittar, Randa, Levasseur, Antoine, Grès, Pierre, Guilbert, Zoé, Zenati, Belkacem, Cherfils, Corinne, Sakka, Mehdi, and Bonnefont-Rousselot, Dominique

Abstract

IntroductionChylous abdominal effusions are serious complications that can be triggered by various aetiologies. The biochemical diagnosis of chyle leakage in ascites or in peritoneal fluid capsules relies on the detection of chylomicrons. Assaying the fluid’s concentration of triglycerides is still the first-line tool. Given that only one comparative study has sought to quantify the value of the triglyceride assay for diagnosing chylous ascites in humans, our objective was to provide practical triglyceride thresholds. Materials and methodsWe conducted a 9-year, retrospective, single-centre study of adult patients and compared a triglyceride assay with lipoprotein gel electrophoresis for the analysis of 90 non-recurring abdominal effusions (ascites and abdominal collections) of which 65 were chylous. ResultsA triglyceride threshold of 0.4 mmol/L was associated with a sensitivity > 95%, and a threshold of 2.4 mmol/L was associated with a specificity > 95%. According to Youden index, the best threshold was 0.65 mmol/L with a sensitivity of 88 (77-95)%, a specificity of 72 (51-88)%, and, in our series, a positive predictive value of 89 (79-95)% and a negative predictive value of 69 (48-86)%. ConclusionsIn our series, cut-off of 0.4 mmol/L could be used for ruling-out diagnosis of chylous effusions, while cut-off of 2.4 mmol/L could be used for reasonably confirming diagnosis.

Published
2023

3. Could the chylomicron marker apoB48 be of value in the diagnosis of chylous effusions?

Author

Lefrère, Bertrand, primary, Sakka, Mehdi, additional, Fourati, Salma, additional, Levasseur, Antoine, additional, Curis, Emmanuel, additional, Cherfils, Corinne, additional, Grès, Pierre, additional, Guilbert, Zoé, additional, Lacorte, Jean-Marc, additional, Chenevière, Cristina, additional, Bittar, Randa, additional, and Bonnefont-Rousselot, Dominique, additional

Published
2023
Full Text
View/download PDF

4. Abstracts of the BIOMED J Congress, Paris

Author

Assami, Hichem, additional, Celse, Tristan, additional, Regueme, Alexandre, additional, Gaillot, Olivier, additional, Soudre, Fabienne, additional, Zerrouki, Loubna, additional, Lorhlam, Hanae, additional, Lasri, Samia, additional, Lyagoubi, Mohamed, additional, Aoufi, Sarra, additional, Sakka, Mehdi, additional, Bittar, Randa, additional, Jomli, Amira, additional, Cherfils, Corinne, additional, Fesel-Fouquier, Valérie, additional, Bonnefont-Rousselot, Dominique, additional, Lauwers, Maïlis, additional, Frikha, Amal, additional, Fage, David, additional, Taccone, Fabio, additional, Cotton, Frédéric, additional, Wolff, Fleur, additional, Barguil, Yann, additional, Chiaradia, Laura, additional, Moulies, Marie-Eve, additional, Otmane, Amel, additional, Sghairi, Emna, additional, Aniba, Rafik, additional, Saadi, Amal Soulef, additional, Durand, Gatien, additional, Marchionini, Charles, additional, Masotti, Julia, additional, Otmane, Adnene, additional, Cheikhrouhou, Fatma, additional, and J, BIOMED, additional

Published
2021
Full Text
View/download PDF

8. Résumés du congrès BIOMED J, Paris.

Author

Assami, Hichem, Celse, Tristan, Regueme, Alexandre, Gaillot, Olivier, Soudre, Fabienne, Zerrouki, Loubna, Lorhlam, Hanae, Lasri, Samia, Lyagoubi, Mohamed, Aoufi, Sarra, Sakka, Mehdi, Bittar, Randa, Jomli, Amira, Cherfils, Corinne, Fesel-Fouquier, Valérie, Bonnefont-Rousselot, Dominique, Lauwers, Maïlis, Frikha, Amal, Fage, David, and Taccone, Fabio

Published
2021
Full Text
View/download PDF

10. Lack of effects of statins on high-density lipoprotein subfractions in HIV-1-infected patients receiving protease inhibitors

Author

Bittar, Randa, Aslangul, Élisabeth, Giral, Philippe, Assoumou, Lambert, Valantin, Marc-Antoine, Kalmykova, Olga, Federspiel, Marie-Christine, Cherfils, Corinne, Costagliola, Dominique, Bonnefont-Rousselot, Dominique, Service de Biochimie Métabolique [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Université Paris Descartes - Paris 5 (UPD5), Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière], Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS - UM 4 (UMR 8258 / U1022)), Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC), Unité de pharmacologie chimique et génétique et d'imagerie (UPCGI - UMR 8151 / UMR_S 1022 ), Université Paris Descartes - Paris 5 (UPD5)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut de Chimie du CNRS (INC), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition ( ICAN ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU Pitié-Salpêtrière [APHP], Université Paris Descartes - Paris 5 ( UPD5 ), Hopital Louis Mourier - AP-HP [Colombes], Service de prévention cardiovasculaire, service d’endocrinologie métabolisme [CHU Pitié-Salpêtrière], Institut Pierre Louis d'Epidémiologie et de Santé Publique ( iPLESP ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), Unité de Technologies Chimiques et Biologiques pour la Santé ( UTCBS - UM 4 (UMR 8258 / U1022) ), Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL ( ENSCP ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Unité de pharmacologie chimique et génétique et d'imagerie ( UPCGI - UMR 8151 / UMR_S 1022 ), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP], Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)-Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL (ENSCP), and Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL (ENSCP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Pravastatine, Risque cardiovasculaire, [ SDV.SP.MED ] Life Sciences [q-bio]/Pharmaceutical sciences/Medication, nutritional and metabolic diseases, Rosuvastatine, [ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, [ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, Cardiovascular risk, HIV-1 population, Rosuvastatin, [ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, HDL distribution, Distribution des HDL, lipids (amino acids, peptides, and proteins), Population VIH-1, Pravastatin
Abstract

The ANRS 126 study group; International audience; Background: We evaluated the effect of 45 days of rosuvastatin or pravastatin treatment on the distribution of HDL subfractions in HIV-1-infected individuals receiving boosted protease inhibitors (PIs) with cardiovascular risk.Methods: The distribution of HDL subclasses by gradient gel electrophoresis was blindly assessed in 74 HIV-1-infected individuals receiving boosted PIs at baseline and at day 45 of statin treatment, and compared with the distribution obtained in 63 healthy normolipidemic individuals taken as controls.Results: No significant modification appeared in HDL distribution between the two arms of statins for the HIV-1-infected individuals. Nevertheless, when compared to controls, HDL subfractions showed a significantly lower HDL2b proportion and significantly higher proportions of HDL2a and HDL3b (P < 0.001).Conclusion: No difference was observed in HDL distribution between pravastatin and rosuvastatin after 45 days treatment, in HIV-1-infected individuals under PIs. Nevertheless, when compared to healthy normolipidemic subjects, HDL distribution is clearly different, with a distribution in HIV-infected individuals under PIs associated with an increased cardiovascular risk.; Contexte: Nous avons évalué l’effet de 45 jours de traitement par la rosuvastatine ou la pravastatine sur la distribution des sous-fractions des HDL chez des personnes atteintes de VIH-1 recevant des inhibiteurs de la protéase boostées (IPs) et ayant un risque cardiovasculaire.Méthodes: La distribution des sous-classes d’HDL effectuée par une électrophorèse sur gel en gradient a été évaluée en aveugle sur 74 personnes infectées par le VIH-1 recevant des inhibiteurs de la protéase boostées (IPs), et ce au jour 0 et après 45 jours de traitement par les statines. Cette distribution a été ensuite comparée à celle obtenue chez 63 personnes en bonne santé, considérées comme témoins.Résultats: Aucune modification significative n’est apparue dans la distribution des HDL entre les deux bras des statines pour les individus infectés par le VIH-1. Néanmoins, comparativement aux témoins, les sous-fractions HDL présentaient une proportion significativement plus faible de HDL2b et des proportions significativement plus élevées de HDL2a et de HDL3b (p < 0,001).Conclusion: Aucune différence dans la modification de la distribution des HDL n’a été observée après 45 jours de traitement entre la pravastatine et la rosuvastatine chez les personnes infectées par le VIH-1 sous IPs. Cependant, la distribution des HDL chez des personnes infectées par le VIH sous IPs est clairement différente quand elle est comparée à celle observée chez les sujets sains, et est associée à un risque cardiovasculaire élevé

Published
2016

11. Lack of effects of statins on high-density lipoprotein subfractions in HIV-1-infected patients receiving protease inhibitors

Author

Bittar, Randa, primary, Aslangul, Élisabeth, additional, Giral, Philippe, additional, Assoumou, Lambert, additional, Valantin, Marc-Antoine, additional, Kalmykova, Olga, additional, Federspiel, Marie-Christine, additional, Cherfils, Corinne, additional, Costagliola, Dominique, additional, and Bonnefont-Rousselot, Dominique, additional

Published
2017
Full Text
View/download PDF

12. Lipoprotein-associated Phospholipase A2 during the Hyperacute Stage of Ischemic and Hemorrhagic Strokes

Author

Rosso, Charlotte, primary, Rosenbaum, David, additional, Pires, Christine, additional, Cherfils, Corinne, additional, Koujah, Nabil, additional, Mestari, Fouzi, additional, Gillet, Emeline, additional, Crozier, Sophie, additional, Sahli-Amor, Mélika, additional, Samson, Yves, additional, Bonnefont-Rousselot, Dominique, additional, and Khani-Bittar, Randa, additional

Published
2014
Full Text
View/download PDF

13. Endogenous CETP activity as a predictor of cardiovascular risk: Determination of the optimal range

Author

Villard, Elise F., primary, Federspiel, Marie-Christine, additional, Cherfils, Corinne, additional, Fesel-Fouquier, Valérie, additional, Bruckert, Eric, additional, Clement, Karine, additional, Bonnefont-Rousselot, Dominique, additional, Le Goff, Wilfried, additional, Bittar, Randa, additional, Couvert, Philippe, additional, and Guerin, Maryse, additional

Published
2013
Full Text
View/download PDF

14. Characterization of two HDL subfractions and LpA-I, LpA-I:A-II distribution profiles and clinical characteristics of hyperalphalipoproteinemic subjects without cholesterol ester transfer protein deficiency.

Author

Sich, Didier, primary, Saı̈di, Youssef, additional, Giral, Philippe, additional, Lagrost, Laurent, additional, Dallongeville, Jean, additional, Federspiel, Marie-Christine, additional, Cherfils, Corinne, additional, Raisonnier, Alain, additional, Turpin, Gérard, additional, and Beucler, Isabel, additional

Published
1998
Full Text
View/download PDF

15. Evaluation of a semi-automatic isoelectric focusing method for apolipoprotein E phenotyping.

Author

Bittar R, Carrié A, Nouadje G, Cherfils C, Fesel-Fouquier V, Barbot-Trystram L, Giral P, and Bonnefont-Rousselot D

Abstract

A qualitative, semi-automatized method for apolipoprotein E (apoE) phenotyping by isoelectric focusing method has been evaluated on 40 serum samples from patients previously genotyped for apoE, especially as regards concordance with genotyping, but also repeatability and reproducibility of the method, and sample storage. Total concordance with genotyping and good precision criteria, together with its practicability and requirement of a little sample volume, lead to conclude to the usefulness of this method to help clinicians in the diagnosis of dyslipidemic and neurodegenerative diseases., Competing Interests: There are no known conflicts of interest., (© 2019 The Authors.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results